Published TCIMAIL newest issue No.199
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 88416-50-6 | Product Number: D4160
Disodium Clodronate Tetrahydrate
×
![]()
×
Purity: >95.0%(T)
Synonyms:
- Clodronic Acid Disodium Salt Tetrahydrate
Product Documents:
| Size | Unit Price | Belgium | Japan* |
|---|---|---|---|
| 1G |
€65.00
|
Contact Us | ≥40 |
| 5G |
€219.00
|
2 | ≥40 |
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | D4160 |
Purity / Analysis Method 
|
>95.0%(T) |
| Molecular Formula / Molecular Weight | CH__2Cl__2Na__2O__6P__2·4H__2O = 360.91 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container
|
5G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 88416-50-6 |
| Related CAS RN
|
22560-50-5 |
| PubChem Substance ID | 253660294 |
| Merck Index (14) | 2371 |
| MDL Number | MFCD02940846 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(Neutralization titration) | min. 95.0 % |
| Water | 18.0 to 22.0 % |
| NMR | confirm to structure |
Properties (reference)
GHS
Related Laws:
Transport Information:
| HS Number | 2931599090 |
Application
Bone Resorption Inhibitor
References
- 1)Bisphosphonates: From bench to bedside
- 2)Computational insights into binding of bisphosphonates to farnesyl pyrophosphate synthase
- 3)Tumour macrophages as potential targets of bisphosphonates
- 4)Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
- 5)Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft
- 6)Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages
- 7)Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects
PubMed Literature
Documents
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.